Why is the A2 Milk share price so resilient?

Despite the overall pessimism, how has the A2 Milk Company Ltd (ASX: A2M) share price bucked the trend and made gains in the past 2 weeks?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor concerns about the impact of coronavirus on global growth has trashed the share price of many stocks, particularly those with direct exposure to China.

Despite the overall pessimism, the A2 Milk Company Ltd (ASX: A2M) share price has bucked the trend and actually made gains in the past 2 weeks. So, why is the A2 Milk share price so resilient?

a woman

Coronavirus and a2 Milk

Despite the doom and gloom, the coronavirus outbreak could actually have a positive impact on a2 Milk and the company's share price. As a public health concern, the conventional thesis is that coronavirus could impact foot traffic and hence the demand for goods and services.

However, some analysts believe that despite a declining demand in physical storefronts, a2 Milk could see a surge in online orders. The assumption is that as consumers are encouraged to stay at home, a2 Milk could see stronger online sales as households look to stockpile on products.

How has a2 Milk performed?

a2 Milk recently impressed the market when the infant formula company reported its results for the half year. The company's performance was highlighted by a 31.6% increase in total revenue to NZ$806.7 million. a2 Milk also saw a 20.5% increase in earnings before interest, tax, depreciation and amortisation (EBITDA) to NZ$263.2 million and 21.1% increase in net profit after tax to NZ$184.9 million.

The company's strong performance was fuelled by strong growth in infant formulas sales, which contributed NZ$659.2 million to total revenue. a2 Milk also saw strong growth in China, with sales of its Chinese labelled infant formula doubling to NZ$146.7 million and distribution growing to 18,300 stores.

a2 Milk anticipates continued strong revenue growth across its key regions and will support this forecast through increased marketing investments in China and the US.

The company also addressed the uncertainty on how the coronavirus could impact its supply chains and demand in China. Despite the uncertainty, management believes that a2 Milk's products will continue to be in strong demand among Chinese families, particularly through online and reseller channels. As a result, a2 Milk expects its EBITDA margin to remain in the 29% – 30% range for the full year.

Should you buy?

Not long ago, some analysts had a sell rating on a2 Milk based on the thesis that the company could not sustain its high margins in a more competitive market. a2 Milk's impressive performance has done enough to change the tune of many analysts. Recently, a note from UBS has a2 Milk rated as a buy with analysts lifting their price target on the infant formula company to $17.69.

In my opinion, any company that performs strongly in current market conditions is one to watch when volatility decreases. I think it would be prudent to keep a2 Milk on a watchlist and wait for the market volatility to subside before making an investment decision.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy hump day session for the ASX.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »